Maimets T - Search Results

1

Pre-administration of PepFect6-microRNA-146a nanocomplexes inhibits inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis.

Urgard E, Lorents A, Klaas M, Padari K, Viil J, Runnel T, Langel K, Kingo K, Tkaczyk E, Langel Ü, Maimets T, Jaks V, Pooga M, Rebane A. Urgard E, et al. Among authors: maimets t. J Control Release. 2016 Aug 10;235:195-204. doi: 10.1016/j.jconrel.2016.06.006. Epub 2016 Jun 3. J Control Release. 2016. PMID: 27269729

2

Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration.

Kristjuhan A, Jaks V, Rimm I, Tooming T, Maimets T. Kristjuhan A, et al. Among authors: maimets t. Oncogene. 1998 May 7;16(18):2413-8. doi: 10.1038/sj.onc.1201749. Oncogene. 1998. PMID: 9620560

3

p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.

Jaks V, Jõers A, Kristjuhan A, Maimets T. Jaks V, et al. Among authors: maimets t. Oncogene. 2001 Mar 8;20(10):1212-9. doi: 10.1038/sj.onc.1204232. Oncogene. 2001. PMID: 11313865

4

Electroporation and carrier DNA cause p53 activation, cell cycle arrest, and apoptosis.

Lepik D, Jaks V, Kadaja L, Värv S, Maimets T. Lepik D, et al. Among authors: maimets t. Anal Biochem. 2003 Jul 1;318(1):52-9. doi: 10.1016/s0003-2697(03)00135-0. Anal Biochem. 2003. PMID: 12782031

5

p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress.

Jõers A, Jaks V, Kase J, Maimets T. Jõers A, et al. Among authors: maimets t. Oncogene. 2004 Aug 19;23(37):6175-85. doi: 10.1038/sj.onc.1207864. Oncogene. 2004. PMID: 15208667

6

ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress.

Pauklin S, Kristjuhan A, Maimets T, Jaks V. Pauklin S, et al. Among authors: maimets t. Biochem Biophys Res Commun. 2005 Aug 26;334(2):386-94. doi: 10.1016/j.bbrc.2005.06.097. Biochem Biophys Res Commun. 2005. PMID: 16004968

7

von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.

Kallas A, Kuuse S, Maimets T, Pooga M. Kallas A, et al. Among authors: maimets t. Thromb Res. 2007;120(6):911-9. doi: 10.1016/j.thromres.2007.02.002. Epub 2007 Mar 21. Thromb Res. 2007. PMID: 17376515

8

CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF.

Kadaja-Saarepuu L, Laos S, Jääger K, Viil J, Balikova A, Lõoke M, Hansson GC, Maimets T. Kadaja-Saarepuu L, et al. Among authors: maimets t. Oncogene. 2008 Mar 13;27(12):1705-15. doi: 10.1038/sj.onc.1210802. Epub 2007 Sep 24. Oncogene. 2008. PMID: 17891181

9

Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein.

Johansson HJ, El-Andaloussi S, Holm T, Mäe M, Jänes J, Maimets T, Langel U. Johansson HJ, et al. Among authors: maimets t. Mol Ther. 2008 Jan;16(1):115-23. doi: 10.1038/sj.mt.6300346. Epub 2007 Nov 6. Mol Ther. 2008. PMID: 17984975 Free article.

10

Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.

Kallas A, Kuuse S, Maimets T, Pooga M. Kallas A, et al. Among authors: maimets t. Acta Haematol. 2008;119(4):244-7. doi: 10.1159/000142614. Epub 2008 Jul 2. Acta Haematol. 2008. PMID: 18594135 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters